Skip to main content

Publications

featured publications

  • Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.

    Therapeutic advances in musculoskeletal disease

    Authors: Sophia H Verspohl, Tobias Holderried, Charlotte Behning, Peter Brossart, Valentin S Schäfer

  • A 78-year-old female with severe tongue pain: benefit of modern ultrasound.

    BMC medical imaging

    Authors: Lara Clarissa Burg, Wolfgang Andreas Schmidt, Peter Brossart, Katharina Isabell Reinking, Franziskus Maria Schützeichel, Robert Patrick Finger, Valentin Sebastian Schäfer

  • Clinical and immunological effects of mRNA vaccines in malignant diseases.

    Molecular cancer

    Authors: Annkristin Heine, Stefan Juranek, Peter Brossart

  • BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells.

    BMC biology

    Authors: Alessio De Magis, Melanie Kastl, Peter Brossart, Annkristin Heine, Katrin Paeschke

  • Helios-expressing CD8 T cells are decreased in patients with systemic lupus erythematosus.

    Lupus

    Authors: Tobias Aw Holderried, Mareike Kruse, Michael Serries, Peter Brossart, Dominik Wolf, Anna Maria Wolf

  • Elotuzumab spares dendritic cell integrity and functionality.

    Journal of cancer research and clinical oncology

    Authors: Sebastian Schlaweck, Leon Strauss, Solveig Daecke, Peter Brossart, Annkristin Heine

  • G-quadruplexes: a promising target for cancer therapy.

    Molecular cancer

    Authors: Nils Kosiol, Stefan Juranek, Peter Brossart, Annkristin Heine, Katrin Paeschke

  • Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah's Witness patient.

    Annals of hematology

    Authors: Sebastian Schlaweck, Peter Brossart, Annkristin Heine

  • Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

    Blood cancer journal

    Authors: Marc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, Uta Bertsch, Hans J Salwender, Markus Munder, Stephan Fuhrmann, Ulrich Dührsen, Peter Brossart, Kai Neben, Jana Schlenzka, Christina Kunz, Marc S Raab, Jens Hillengaß, Anna Jauch, Anja Seckinger, Dirk Hose, Steffen Luntz, Pieter Sonneveld, Henk Lokhorst, Hans Martin, Martin Goerner, Martin Hoffmann, Hans-Walter Lindemann, Helga Bernhard, Igor W Blau, Christof Scheid, Britta Besemer, Katja C Weisel, Mathias Hänel, Jan Dürig, Hartmut Goldschmidt

  • CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).

    Cancer immunology, immunotherapy : CII

    Authors: Simon Fietz, Romina Zarbl, Dennis Niebel, Christian Posch, Peter Brossart, Gerrit H Gielen, Sebastian Strieth, Torsten Pietsch, Glen Kristiansen, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich